Abstract: The present invention relates to methods of selecting, screening, engineering, making and modifying antibodies that have improved bioavailability upon subcutaneous administration to a human. Antibodies and variant antibodies with improved bioavailability upon subcutaneous administration to a human are also described.

Abstract: Methods and apparatus that may perform a drag-and-drop operation for a geographical query in a digital map are provided with reduced or minimum textual input. In one example, the method includes providing, by one or more processors, a digital map for display on a computing device, providing, by the one or more processors, a preformulated query for display in a user interface, receiving an input applied to the preformulated query, wherein the input indicates an application of the preformulated query to a selected region of the digital map, and performing, by the one or more processors, a geographic search based on the input applied to the preformulated query.

Abstract: The present invention relates to TrkB binding agonists, and to the use of such agonists in the treatment of neurological disorders and other disorders. The present invention also relates to specific TrkB binding agonists comprising CDRs, variable regions, heavy and light chains, and variant sequences thereof.

Abstract: A distributed navigation system architecture includes a plurality of navigation platforms, each having a universal navigation processor configured to communicate with other universal navigation processors, one or more relative navigation systems configured to provide source information to the navigation platforms, an anchor navigation node disposed on one or more of the plurality of navigation platforms in order to form one or more anchor navigation platforms, the anchor navigation node, including an inertial navigation system, a clock, and one or more absolute navigation systems, configured to determine navigation information based on the inertial navigation system, the clock, the one or more absolute navigation systems and optionally the source information, the one or more anchor navigation platforms providing the navigation information to the other navigation platforms, and a navigation processor system in communication with each of the universal navigation processors in order to provide operating informat

Abstract: The present invention relates to a recombinant signal sequence derived from E. coli. The invention also relates to a fusion protein comprising the signal sequence, a recombinant protein and methods of producing the recombinant protein. The recombinant signal sequence can be used to provide a method for controlling the viscosity of the fermentation, and/or controlling basal (pre-induction) expression of the recombinant protein.

Abstract: The present invention relates to TrkB binding agonists, and to the use of such agonists in the treatment of neurological disorders and other disorders. The present invention also relates to specific TrkB binding agonists comprising CDRs, variable regions, heavy and light chains, and variant sequences thereof.

Abstract: The present disclosure relates to compositions comprising antibody variants, for treating interleukin 5 (IL-5) mediated diseases, and related methods.

Abstract: The present invention relates to modified proteins and peptides that have reduced ability to bind to pre-existing antibodies. Such modified protein/peptide molecules can comprise C-terminal additions, extensions or tags and/or certain amino acid substitutions. Such modified molecules (e.g. fusions and conjugates) comprise proteins, peptides, antigen binding molecules, antibodies or antibody fragments such as single variable domains e.g. human immunoglobulin (antibody) single variable domains, and also single variable domains derived from non-human sources such as a llama or camel, e.g. a VHH including a Nanobody™ (described in e.g. WO 94/04678 and WO 95/04079 inter alia). The invention further relates to uses, formulations, compositions comprising such modified C terminally extended and/or amino acid substituted molecules and also to methods of production and expression of these molecules.

Abstract: This invention relates to methods and compositions for detecting, diagnosing, preventing, treating or ameliorating the symptoms of a demyelinating condition selected from: enterotoxemia (ET), multiple sclerosis (MS), clinically definite MS (CDMS), clinically isolated syndrome (CIS), neuromyelitis optica spectrum disorder (NMOSD), optic neuritis (ON), neuromyelitis optica (NMO), myelitis, myelitis, transverse myelitis (TM), a disease or condition characterised by the increase or presence of antibodies against aquaporin-4 (AQP-4) and/or astrocyte damage, and acute disseminated encephalomyelitis (ADEM) in a human or animal subject in need.

Abstract: The present invention relates to methods of selecting, screening, engineering, making and modifying antibodies that have improved bioavailability upon subcutaneous administration to a human. Antibodies and variant antibodies with improved bioavailability upon subcutaneous administration to a human are also described.

Abstract: The amplitude control assembly for an oral care appliance includes a capacitance-sensing touch array (26) responsive to the position of a user's touch thereon to change the value of capacitance from the array, as determined by a sensor (30). A control assembly (24), responsive to the change of capacitance, changes an operating characteristic of the drive signal for the appliance, to change the amplitude of motion of a workpiece portion of the oral care appliance.

Abstract: The present disclosure relates to modified proteins and peptides that have reduced ability to bind to pre-existing antibodies. Such modified protein/peptide molecules can comprise C-terminal additions, extensions or tags and/or certain amino acid substitutions. Such modified molecules (e.g., fusions and conjugates) comprise proteins, peptides, antigen binding molecules, antibodies or antibody fragments such as single variable domains. The disclosure further relates to uses and formulations of compositions comprising such modified C-terminally extended and/or amino acid substituted molecules and also to methods of production and expression of these.

Abstract: Systems, devices, and methods are described for the assessment, screening, monitoring, or diagnosis of developmental or cognitive conditions, including autism spectrum disorders (ASD) by analysis of eye tracking data generated from feedback received as a result of display of specific predetermined visual stimuli to a subject or patient. Subsequent to a calibration phase, a testing procedure is performed by presenting predetermined stimuli (e.g., videos) to a subject via a display device. Eye tracking data (from the subject moving his or her eyes in response to predetermined movies or other visual stimuli) are collected. During the data collection period, the system periodically presents targets to reflexively elicit the subject's gaze. These data are used to later verify accuracy. Analysis of the subject's viewing patterns during these stimuli is used for the assessment, screening, monitoring, or diagnosis of developmental or cognitive conditions such as ASD.

Abstract: The present invention concerns antigen binding proteins and fragments thereof which specifically bind B Cell Maturation Antigen (BCMA), particularly human BCMA (hBCMA) and which inhibit the binding of BAFF and APRIL to the BCMA receptor. Further disclosed are pharmaceutical compositions, screening and medical treatment methods.

Abstract: The present invention relates to TrkB binding agonists, and to the use of such agonists in the treatment of neurological disorders and other disorders. The present invention also relates to specific TrkB binding agonists comprising CDRs, variable regions, heavy and light chains, and variant sequences thereof.

Abstract: Systems and methods are disclosed for calculating dynamic ambient occlusion (AO) values for character models to yield high-quality approximations of global illumination effects. The approach utilizes a dual component machine-learning model that factorizes dynamic AO computation into a non-linear component, in which visibility is determined by approximating spheres and their casted shadows, and a linear component that leverages a skinning-like algorithm for efficiency. The parameters of both components are trained in a regression against ground-truth AO values. The resulting model accommodates lighting interactions with external objects and can be generalized without requiring carefully constructed training data.

Abstract: This application discloses antigen binding proteins that bind Lymphocyte Activation Gene 3 (LAG-3), and more particularly to antigen binding proteins that cause depletion of LAG-3+ activated T cells.

Abstract: Antigen binding proteins that bind Lymphocyte Activation Gene 3 (LAG-3), and more particularly to antigen binding proteins that cause depletion of LAG-3+ activated T cells.

Abstract: Methods, systems, and apparatus, including computer programs encoded on computer storage medium for implementing the advertisement of device status information. In one aspect, configuration data for the second device is obtained, where the configuration data indicating a current operating mode of the second device or a user-specified configuration of the second device. The stored radio transmitter identifier is accessed from the one or more data storage devices. A first advertisement that indicates the radio transmitter address and the radio transmitter identifier is generated. A second advertisement is generated that indicates the radio transmitter address and an encoding of the configuration data for the second device. Using the radio transmitter, a series of advertisements that includes at least the first advertisement and the second advertisement is broadcasted.

Abstract: This application discloses antigen binding proteins that bind Lymphocyte Activation Gene 3 (LAG-3), and more particularly to antigen binding proteins that cause depletion of LAG-3+ activated T cells.